Author

Edwin J. Iwanowicz

ORCID 0009-0005-0690-3301Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

Lee M. GravesiD· 2 shared Adrienne D. CoxiD· 1 shared Amber M. AmparoiD· 1 shared Anjali DhalliD· 1 shared Brandon L. MoueryiD· 1 shared Channing J. DeriD· 1 shared Chuong D. HoangiD· 1 shared Clint A. StalneckeriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Lee M. GravesORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 11, 2026

TR-107, a novel mitochondrial ClpP agonist, induces robust antitumor activity against preclinical models of adrenocortical carcinoma

George I Karadimov, Yoo Sun Kim, Haiqing Fu…·Jaydira Del Rivero

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

DOI 10.64898/2026.08.10.743339

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 3, 2025

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance

Kristina Drizyte‐Miller, Seamus E. Degan, Ryan D. Mouery…·Channing J. Der

This study shows that ONC201 inhibits KRAS-mutant pancreatic cancer growth and overcomes resistance to RAS inhibitors by activating ClpP and altering metabolic pathways.

3 citations

humanexperimental assay

𝕏 PostBluesky